IRB #

STUDY00020580

Title

DCC-2618-99-001: Expanded Access Program for Ripretinib in Patients with Locally Advanced Unresectable or Metastatic GIST Who Have Received Treatment with Prior Therapies

Principal Investigator

Michael Heinrich

Study Purpose

This Expanded Access Program is intended to provide access to ripretinib (DCC-2618) treatment for patients with locally advanced unresectable or metastatic GIST. Additionally, it aims to further characterize the safety and effectiveness of ripretinib.

Medical Condition(s)

Gastrointestinal Stromal Tumors (GIST)

Eligibility Criteria

1. Male or female patients, ≥ 18 years of age at the time of informed consent
2. Histologic diagnosis of GIST
3. Patients must have received prior treatment with at least 2 of the FDA approved drugs for GIST: imatinib, sunitinib, and regorafenib.

Additional criteria may apply.

Age Range

18 - 100

Healthy Volunteers Needed

No

Duration of Participation

This is an expanded access study and, thus, no sample size and no power computation will be performed. Patient will receive ripretinib until it becomes commercially available or the Sponsor chooses to discontinue the program.

Minors Included

No

Contact

Knight Clinical Trials Information Line
503-494-1080
trials@ohsu.edu

Sponsor

Deciphera Pharmaceuticals

Recruitment End

10/31/2021

Compensation Provided

No


Go Back